Graybug vision stock
Should you hold graybug vision (gray) stock? Stock market analysts on Wall Street agree that investors should own Graybug Vision stock. The Holding's rating indicates that analysts believe that investors should maintain existing positions in GRIS, but not buy additional shares or sell existing shares. View analyst ratings for Graybug Vision or top rated stocks.
What is the price of a share in graybug vision?
The company has issued 4,700,000 shares at $$ per share. SVB Leerink and Piper Sandler were the IPO underwriters, while Needham & Co. and Wedbush PacGrow were co-chairs. What is the stock symbol for Graybug Visions? Graybug Vision is listed on NASDAQ under the symbol GRAY. How can I buy Graybug Vision shares?
What is graygraybug vision?
Vision Graybug, Inc. develops drugs for the eyes. It focuses on developing drug delivery methods for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded in May 2011 by Justin S. Haynes, Peter John McDonnell, Christy Wiskil and Peter A. Campociaro and is headquartered in Redwood City, California.
Who underwrote graybug vision's IPO?
SVB Leerink and Piper Sandler acted as underwriters for the IPO, while Needham & Co. and Wedbush PacGrow were co-managers. What is the stock symbol for Graybug Visions?
Is graybug vision (graybug) stock a buy or sell?
Graybug Vision received a consensus rating from Hold. The average business score is , based on 2 buy ratings, 4 hold ratings, and no sales ratings. Based on analysts' price target in USD, Graybug Vision has upside potential relative to the current USD price.
How many shares of graybug vision are shorted?
On December 31, the number of short positions was 115,600 shares, compared to 173,600 shares on December 15. Based on an average daily trading volume of 160,900 stocks, the days-to-coverage ratio is currently days. The shares are currently being sold short. See Graybug Vision's brief interest.
How do I contact graybug?
The company can be reached by phone 6504872800 or by email ir@. Find out the latest news, bid/ask prices, SEC filings and insider trading on your stocks. Compare your portfolio's performance against major indices and receive personalized stock offers based on your portfolio.
Do analysts agree on graybug vision's (graybug) price target?
The average business score is , based on 2 buy ratings, 4 hold ratings, and no sales ratings. Based on analyst consensus, Graybug Vision's USD price target sees upside potential relative to the current USD price. Graybug Vision has only been the subject of 2 investigative reports in the past 90 days.
What was the price of graybug vision IPO?
(GRAY) raised $75 million in an initial public offering (IPO) on Friday, September 25, 2020. The company has issued 4,700,000 shares at a price of $$ per share. SVB Leerink and Piper Sandler were the IPO underwriters, while Needham & Co. and Wedbush PacGrow were co-managers. What is the stock symbol for Graybug Visions?
![:brown_circle:]( ":brown_circle:")
What is the upside for graybug vision's stock?
Your forecast varies between $ and $. On average, they expect Graybug Visions' stock price to hit $100 next year. This indicates a possible rise in the current share price. Check out analysts' price targets at Graybug Vision or the top-rated stocks from Wall Street analysts.
What are analysts'target prices for graybug vision's shares?
6 analysts have published an annual target price for Graybug Visions stock. Your forecast varies between $ and $. On average, they expect Graybug Visions' stock price to hit $100 next year. This indicates a possible rise in the current share price.
Does graybug vision boast high insider ownership?
Graybug Vision stock is owned by insiders. A high percentage of internal ownership can be a sign of a company's health. Graybug Vision shares are owned by institutions.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
When is graybug vision's next quarterly earnings release?
Graybug Vision plans to release its next quarterly earnings report on Thursday, March 3, 2022. View Graybug Vision's earnings forecast. What was Graybug Visions' revenue last quarter?
What is the price of a share in graybug vision products
Share Price $ (Finday Close) General Information Description Graybug Vision Inc. is a clinical-stage biopharmaceutical company developing transformative medicines for the treatment of retinal and optic nerve disorders.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What is the price of a share in graybug vision health
Graybug Vision shares are trading at a price of $ per share, with a total value of Graybug Vision shares (market capitalization) of $. Graybug Vision shares were originally listed on September 25, 2020 at a price of $.
![:eight_spoked_asterisk:]( ":eight_spoked_asterisk:")
What is the price of a share in graybug vision llc
Graybug Vision maintains a normal fair value of $ per share. The company's current price is $ Today, the company seems undervalued.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Where is graybug Vision Inc located?
The company was previously known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is headquartered in Redwood City, California.
![:brown_circle:]( ":brown_circle:")
What is the price of a share in graybug vision insurance
GRAYBUG VISION, INC. (Issuer Name) Ordinary Shares, par value $ per share .
Why choose graybug vision?
Graybug Vision believes that the world should be a place of radiance, clarity, light and hope. they see you! For people with chronic diseases of the retina and optic nerve, they are developing drugs that make healthy vision more accessible and manageable, and improve adherence and vision.
What is graygray vision?
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, develops drugs to treat diseases of the retina and optic nerve.
![:brown_circle:]( ":brown_circle:")
What is graybug’s technology?
“I am excited about Graybug's technology for the sustained delivery of pharmacological agents to the eye. It can improve the actual outcome of patients with retinal disorders by reducing the need for treatment.
![:brown_circle:]( ":brown_circle:")
Is graybug's gb-102 effective for wet age-related macular degeneration?
Graybug Vision Inc (NASDAQ: GRAY) presented a comprehensive analysis of data from the 18-month ALTISSIMO Phase 2b GB102 study in wet age-related macular degeneration (wet AMD). GB102 is Graybugs' patented sunitinib malate administered intravitrealally twice a year.
What is gray graybug vision loss
Graybug Vision maintains a negative resource cost (as a percentage) and loses $ for every dollar of company-owned resources. The unsuccessful use of assets confirms that the company is less efficient with every dollar of resources it retains.
What is graybug gb-102?
GB102 is Greybugs' patented sunitinib malate, which is administered intravitrealally twice a year. Related link: Graybug Vision reports a comprehensive data analysis after one year of treatment of wet AMD with GB102.
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
What is gray graybug vision test
GRAY Technical Analysis A quick and easy way to analyze US stocks. Technical analysis indicators show real-time rankings for selected time frames. Summary of Graybug Vision, Inc. based on the most popular technical indicators: moving averages, oscillators and pivots.
![:brown_circle:]( ":brown_circle:")
What is graygraybug’s polymer delivery system?
Graybug's polymer delivery systems are designed to form deposits near the fundus of the eye beyond the visual axis, either via an injectable implant or as microparticles added after intravitreal injection (IVT).
![:diamond_shape_with_a_dot_inside:]( ":diamond_shape_with_a_dot_inside:")
Is graybug vision a good company?
The company was previously known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is headquartered in Redwood City, California. Graybug Vision received a consensus rating from Hold.
